ATTAIN: Peginterferon beta-1a remains efficacious for MS in long term

VANCOUVER – Peginterferon beta-1a has durable efficacy for the treatment of relapsing-remitting multiple sclerosis, according to data from the ATTAIN extension study of a phase III trial. With...
Source: Clinical Neurology News - Category: Neurology Source Type: news